stockportfolio.pro
Johnson & Johnson (JNJ)
Healthcare · Drug Manufacturers - General · NYSE
Johnson & Johnson revenue & earnings — last 10 fiscal years
| Metric | 2017 | 2017 | 2018 | 2019 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71.89B | $76.45B | $81.58B | $82.06B | $82.58B | $78.74B | $94.94B | $85.16B | $88.82B | $94.19B |
| Gross profit | $50.10B | $51.01B | $54.49B | $54.50B | $54.16B | $55.34B | $55.39B | $58.61B | $61.35B | $63.94B |
| Net income | $16.54B | $1.30B | $15.30B | $15.12B | $14.71B | $20.88B | $17.94B | $35.15B | $14.07B | $26.80B |
| Net margin | 23.0% | 1.7% | 18.8% | 18.4% | 17.8% | 26.5% | 18.9% | 41.3% | 15.8% | 28.5% |
Source: Johnson & Johnson SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into JNJ stock?
At today's market cap of $570.51B, Johnson & Johnson is priced for free-cash-flow growth of about 12.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $19.70B from the FY ending 2025-12-31). For comparison, free cash flow actually grew -0.5%/yr over the last five fiscal years and revenue 2.7%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Johnson & Johnson financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track JNJ in your portfolio →
Johnson & Johnson financial history by metric
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Johnson & Johnson — frequently asked questions
What is Johnson & Johnson's revenue?
Johnson & Johnson (JNJ) reported revenue of $94.19B for fiscal year 2025, up 6.0% from the prior year, according to its SEC filings.
Is Johnson & Johnson profitable?
Yes. JNJ earned net income of $26.80B in fiscal 2025, a net margin of 28.5%.
What is JNJ's P/E ratio?
Johnson & Johnson trades at a price-to-earnings ratio of about 26.9 based on the latest data in our nightly-refreshed cache.
How fast is Johnson & Johnson growing?
JNJ's revenue grew at roughly 2.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Johnson & Johnson have?
As of fiscal year 2025, JNJ carried roughly $49.93B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Johnson & Johnson's gross margin?
JNJ's gross margin was 67.9% in fiscal 2025 — gross profit of $63.94B on revenue of $94.19B.
What is Johnson & Johnson's market cap?
Johnson & Johnson (JNJ) has a market capitalization of about $570.51B, based on the latest data in our nightly-refreshed cache.
When does Johnson & Johnson's fiscal year end?
JNJ's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into JNJ stock?
At today's market cap of $570.51B, Johnson & Johnson is priced for free-cash-flow growth of about 12.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $19.70B from the FY ending 2025-12-31). For comparison, free cash flow actually grew -0.5%/yr over the last five fiscal years and revenue 2.7%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Johnson & Johnson's official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.